Running out of cash and cited on fraud charges, ImmunoCellular retreats on PhIII and cries for help
Things just keep getting worse and worse at ImmunoCellular Therapeutics $IMUC.
Three and a half years after its lead cancer vaccine flopped in a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
